Screening one composite medication list pair by pair, the Week 10 drug interaction screening report within NURS 6521 classifies each interaction by mechanism and severity and states the decision each prompts. Searches like "nurs 6521 week 10 assignment example", "nurs6521 week 10 sample" and "nurs 6521 week 10 example" land here.
The NURS 6521 Week 10 example, in full
Drug Interaction Screening Report: Adding Clarithromycin to a Six-Drug Regimen in a 71-Year-Old Woman
Student Name
College of Nursing, Walden University
NURS 6521: Advanced Pharmacology
Instructor Name
Month Day, Year
Drug Interaction Screening Report: Adding Clarithromycin to a Six-Drug Regimen in a 71-Year-Old Woman
Patient and Medication List
Mrs. V.H. is fictional. She is 71, lives independently, and was seen at an urgent care center for facial pain and purulent nasal drainage lasting 12 days; she was prescribed clarithromycin 500 mg twice daily for ten days. She brought the new prescription to her primary care follow-up before filling it. Her existing medications are simvastatin 20 mg nightly for hyperlipidemia, citalopram 20 mg daily for depression, tramadol 50 mg up to three times daily as needed for knee osteoarthritis, lisinopril 10 mg daily for hypertension, and metformin 500 mg twice daily for type 2 diabetes. Her estimated glomerular filtration rate is 64 mL/min/1.73 m2, her potassium is normal, and a baseline electrocardiogram last year showed a corrected QT interval of 452 ms.
Method
Every pair among the six drugs was screened, giving 15 pairs. Severity is recorded on a four-level scale (contraindicated, major, moderate, minor or none) as returned by the practice's electronic interaction checker, and each flagged rating was confirmed against the product labeling or the primary literature cited below. Each pair is also classified by mechanism type, pharmacokinetic (one drug changes the concentration of the other) or pharmacodynamic (the drugs add to or oppose each other's effects at the site of action), because the type determines which decisions can resolve it. Over-the-counter products and supplements were asked about directly and none are taken, and her allergy list records no drug allergies. Kidney function and the baseline electrocardiogram were checked before screening, since both change how much weight an interaction deserves in an older adult.
Screening Table
Clarithromycin + simvastatin: contraindicated; pharmacokinetic; action required.
Clarithromycin + citalopram: major; pharmacodynamic (additive QT prolongation), with a minor pharmacokinetic component; action required.
Citalopram + tramadol: major; pharmacodynamic (additive serotonergic effect, lowered seizure threshold); action required.
Clarithromycin + tramadol: moderate; pharmacokinetic (CYP3A4 inhibition raises tramadol exposure); resolved by the clarithromycin decision.
Clarithromycin + lisinopril: none of concern; no action.
Clarithromycin + metformin: none of concern; no action.
Simvastatin + citalopram: none of concern; no action.
Simvastatin + tramadol: none of concern; no action.
Simvastatin + lisinopril: none of concern; no action.
Simvastatin + metformin: none of concern; no action.
Citalopram + lisinopril: minor (both can contribute to hyponatremia in older adults); monitor sodium; no change.
Citalopram + metformin: none of concern; no action.
Tramadol + lisinopril: none of concern; no action.
Tramadol + metformin: minor (tramadol has rarely been associated with hypoglycemia); no change.
Lisinopril + metformin: minor (ACE inhibitors may slightly enhance glucose lowering); no change.
Flagged Pair 1: Clarithromycin and Simvastatin
Most of an oral simvastatin dose is cleared by CYP3A4 in the intestinal wall and then the liver before it ever reaches the circulation, so only a small fraction arrives intact. Clarithromycin is a strong CYP3A4 inhibitor. Combined, simvastatin exposure can rise many-fold, and high statin concentrations in skeletal muscle cause myopathy and, at worst, rhabdomyolysis with acute kidney injury. The simvastatin labeling lists strong CYP3A4 inhibitors, including clarithromycin, as contraindicated. The risk is not theoretical: in a population-based study of older adults taking statins metabolized by CYP3A4, coprescription of clarithromycin was associated with higher rates of hospitalization for rhabdomyolysis and acute kidney injury than coprescription of azithromycin (Patel et al., 2013).
Flagged Pair 2: Clarithromycin and Citalopram
Both drugs block the rapid component of the delayed rectifier potassium current in cardiac myocytes, prolonging ventricular repolarization and the QT interval, and prolonged repolarization can trigger torsades de pointes (Roden, 2004). Their effects add. Mrs. H. has several additional risk factors: female sex, age over 65, and a baseline corrected QT already at 452 ms. The FDA's revised labeling for citalopram warns of dose-dependent QT prolongation, limits the maximum dose to 20 mg daily in patients over 60, and advises caution with other drugs that prolong the QT interval (U.S. Food and Drug Administration [FDA], 2012). She is already at that maximum.
Flagged Pair 3: Citalopram and Tramadol
Tramadol inhibits serotonin and norepinephrine reuptake in addition to its opioid effect, and citalopram is a selective serotonin reuptake inhibitor. Together they raise synaptic serotonin, and excess serotonergic activity produces serotonin syndrome: agitation, tremor, hyperreflexia, clonus, sweating, and in severe cases hyperthermia (Boyer & Shannon, 2005). Tramadol also lowers the seizure threshold, a risk that increases with concomitant antidepressants. She has used tramadol only intermittently, which reduces but does not remove the risk, and older adults are more vulnerable to its central effects.
Decisions
One change resolves two major problems and a third moderate one: replacing clarithromycin with a different antibiotic class. A pharmacokinetic interaction can sometimes be managed by substitution within a class, but here both of clarithromycin's flagged interactions follow from properties the macrolide itself carries, CYP3A4 inhibition and QT prolongation. The indication also supports the change. For acute bacterial rhinosinusitis, the IDSA guideline recommends amoxicillin-clavulanate as first-line therapy and advises against macrolides because of high rates of pneumococcal resistance (Chow et al., 2012). Amoxicillin-clavulanate 875/125 mg twice daily for five to seven days is prescribed instead. It does not inhibit CYP3A4 and does not prolong the QT interval, so the simvastatin and citalopram pairs are resolved without touching either long-term medication, and the clarithromycin-tramadol pair disappears with it.
The citalopram and tramadol pair is pharmacodynamic, and additive effects are rarely managed by adjusting doses; one agent usually needs to go. Her depression has been stable on citalopram for three years, so tramadol is the agent replaced. Acetaminophen up to 3 g daily is recommended for her knee pain, with topical diclofenac for flares, which avoids both the serotonergic interaction and the renal and gastrointestinal risks of oral anti-inflammatory drugs at her age.
Simvastatin does not need to be held, since the interacting antibiotic is no longer being given.
Rescreen of the Revised List
The revised list, amoxicillin-clavulanate, simvastatin, citalopram, acetaminophen, topical diclofenac, lisinopril, and metformin, was screened again pair by pair. No contraindicated or major interactions were returned. The minor citalopram and lisinopril pair remains, managed with a sodium check at her next routine laboratory draw, and the minor lisinopril and metformin pair requires no action. Mrs. H. is taught the symptoms that would have signaled the interactions that were avoided, unexplained muscle pain or weakness with dark urine, palpitations or fainting, and agitation with tremor or muscle jerking, so that she can report them if any drug on her list changes in the future.
References
Boyer, E. W., & Shannon, M. (2005). The serotonin syndrome. New England Journal of Medicine, 352(11), 1112-1120. https://doi.org/10.1056/NEJMra041867
Chow, A. W., Benninger, M. S., Brook, I., Brozek, J. L., Goldstein, E. J. C., Hicks, L. A., Pankey, G. A., Seleznick, M., Volturo, G., Wald, E. R., & File, T. M., Jr. (2012). IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clinical Infectious Diseases, 54(8), e72-e112. https://doi.org/10.1093/cid/cis370
Patel, A. M., Shariff, S., Bailey, D. G., Juurlink, D. N., Gandhi, S., Mamdani, M., Gomes, T., Fleet, J., Hwang, Y. J., & Garg, A. X. (2013). Statin toxicity from macrolide antibiotic coprescription: A population-based cohort study. Annals of Internal Medicine, 158(12), 869-876. https://doi.org/10.7326/0003-4819-158-12-201306180-00004
Roden, D. M. (2004). Drug-induced prolongation of the QT interval. New England Journal of Medicine, 350(10), 1013-1022. https://doi.org/10.1056/NEJMra032426
U.S. Food and Drug Administration. (2012). FDA drug safety communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related
What a finished NURS 6521 Week 10 drug interaction screening report looks like
A screening table leads the report: every pair on the list, the interaction resource's severity rating, whether the mechanism is pharmacokinetic or pharmacodynamic, and the decision taken. Most rows read no interaction of concern. Three do not. The macrolide inhibits the hepatic enzyme that clears the statin, raising the risk of muscle toxicity; the SSRI and the pain reliever together add serotonergic effect; and the macrolide brings a second agent able to prolong the QT interval alongside the SSRI. Each of the three receives a paragraph of mechanism and a decision. Choosing a different antibiotic class removes both macrolide problems at once, and a non-serotonergic analgesic replaces the pain reliever. A final section confirms that the revised list was screened again and records the result.
How a NURS 6521 Week 10 example is structured
Completeness is the principle behind the layout. Screening every pair, including the uneventful ones, demonstrates method in a way that discussing only the famous interactions cannot, so the table precedes the analysis and includes rows that required no action. Analysis then follows severity, highest first. Each flagged pair is explained by mechanism before any decision is stated, and the mechanism type matters to the decision: a pharmacokinetic interaction can sometimes be managed by substitution within a class, while an additive pharmacodynamic effect usually needs one agent removed. The report shows that a single change, replacing the antibiotic class, resolves two flagged pairs at once, which is the economy a prescriber looks for. Rescreening the revised list closes the loop, and the named interaction resource is cited throughout.
Every pair, including the quiet ones
Four agents give six pairs, and every one is shown. Rows marked no action are evidence of method, not padding, and they are kept in the table.
Enzyme inhibition and the statin
The macrolide blocks the enzyme responsible for the statin's clearance, so statin exposure rises. The paragraph explains why that matters for skeletal muscle.
Additive serotonergic effect
Two agents that each increase serotonin activity add together. The report explains this pharmacodynamic mechanism and substitutes the analgesic.
One substitution, two problems solved
Choosing a different antibiotic class removes both the enzyme interaction and the added QT effect, which the report identifies as the decisive move.
Rescreened after revision
The new list is run through the same resource and the result recorded, confirming that no substitution introduced a fresh interaction of its own.
Where marks go in NURS 6521 Week 10
Systematic method is the criterion reports most often miss, since discussing two well-known interactions shows recall, while screening every pair shows a process a prescriber could repeat. Mechanism classification is scored next, and confusing a pharmacokinetic interaction with a pharmacodynamic one leads to decisions that do not follow. Decisions are graded for proportion. Stopping every flagged drug is as weak as accepting every risk, and the strongest reports use one change to resolve several problems. Severity ratings must be attributed to a named resource, because unsourced ratings cannot be checked. Rescreening often carries a small separate mark, and counseling about symptoms of the flagged interactions completes the content rows before formatting is considered.
Get a NURS 6521 Week 10 example written to your instructions
The list in your prompt, whether four drugs or ten, determines how long the screening table runs, so send it with the rubric and the prompt text, and name the interaction resource your course relies on. Your report comes back in 24 to 48 hours built on that list, and the first custom one is free.
NURS 6521 Week 10 questions, answered
Which interaction resource does the report use?
Lexicomp's interaction checker, cited for its severity ratings for drug pairs. Many courses name a different resource, and ratings between resources do not always agree, so the report attributes each rating to its source. If your section specifies a resource, the table is rebuilt with that resource's ratings so the evidence matches what your grader will check.
How does screening differ from medication reconciliation?
No. Reconciliation compares lists across a transition of care to catch omissions and duplications. This report assumes the list is accurate and asks what happens when its agents meet in one body. Some prompts combine both tasks, and if yours does, the reconciliation step appears first, followed by the screening table built from the reconciled list.
Was the medication list taken from a patient?
It is fabricated for teaching. The four agents were chosen because they produce one pharmacokinetic interaction, one pharmacodynamic interaction and an additive QT effect, which lets a short report show three distinct mechanisms. No record was consulted in building it. A list from your own practice should be stripped of identifiers before it appears in anything you submit.